STUDY ON ANTI-HYPERTENSIVES IN PREECLAMPSIA

Pre-eclampsia is a multi-organ system disorder that occurs after the 20th week of gestation in pregnancy and is characterized by hypertension and proteinuria with or without edema. It is a major cause of morbidity and mortality for the woman and her child. The aim of this study was to investigate the efficiency of the short-term treatment with antihypertensives in women with preeclampsia and to evaluate the maternal and neonatal outcomes. In present study, the higher incidence of preeclampsia is seen in primigravidas. After the use of antihypertensives, the systolic BP reduced from 150.58 ± 16.97 mmHg (mean ± SD) to 132.5 ± 11.35 mmHg (p-value <0.0001). Diastolic BP before and after treatment were 100.07 ± 11.83 mmHg and 85.19 ± 8.52 mmHg respectively (p-value < 0.0001). By examining the neonatal outcome, it is observed that 7.6 % neonates developed fetal distress, intrauterine growth retardation (IUGR) (5.7 %), low birth weight (LBW) babies (5.7 %) and 1.92 % neonatal death occurred. Only lesser percentage of fetal or neonatal adverse effects were occurred in the patients who is receiving antihypertensives. Among antihypertensives used, methyldopa with nifedipine combination is much effective in controlling blood pressure with minimal maternal and neonatal adverse effects in preeclamptic patients.